KPTI
Karyopharm Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.79
+1.13%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 146.6M | 146.1M | 145.2M | 146.0M | 157.1M |
| Cost of Revenue | 6.0M | 5.9M | 6.0M | 4.9M | 5.2M |
| Gross Profit | 140.6M | 140.1M | 139.2M | 141.1M | 151.9M |
| Operating Expenses | |||||
| R&D Expense | 121.9M | 125.6M | 143.2M | 138.8M | 148.7M |
| SG&A Expense | 102.0M | 105.2M | 115.4M | 131.9M | 145.4M |
| General & Admin Expense | 102.0M | 105.2M | 115.4M | 131.9M | 145.4M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (988.0K) | — | — | — | — |
| Total Operating Expenses | 222.9M | 230.8M | 258.7M | 270.6M | 294.1M |
| Cost and Expenses | 229.0M | 236.8M | 264.7M | 275.6M | 299.3M |
| Operating Income (EBIT) | (82.3M) | (90.7M) | (119.4M) | (129.5M) | (142.2M) |
| Non-Operating | |||||
| Interest Income | 2.4M | 2.8M | 7.4M | 10.9M | 2.4M |
| Interest Expense | 49.3M | 45.8M | 37.4M | 23.8M | 25.0M |
| Net Interest Income | (46.9M) | (43.1M) | (30.0M) | (12.9M) | (22.6M) |
| Other Non-Op Income/Expense | (142.4M) | (105.3M) | 43.1M | (13.2M) | (22.7M) |
| Non-Operating Income (excl Interest) | 93.7M | 59.4M | (80.5M) | (10.6M) | (2.3M) |
| EBT (Pre-Tax Income) | (224.8M) | (196.0M) | (76.4M) | (142.8M) | (164.9M) |
| Income Tax Expense | (32.0K) | 43.0K | 57.0K | 323.0K | 369.0K |
| Bottom Line | |||||
| Net Income | (224.7M) | (196.0M) | (76.4M) | (143.1M) | (165.3M) |
| Earnings from Cont. Ops | (224.7M) | (196.0M) | (76.4M) | (143.1M) | (165.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (232.9M) | (196.0M) | (76.4M) | (143.1M) | (165.3M) |
| Per Share | |||||
| Basic EPS | ($22.32) | ($17.93) | ($9.41) | ($18.79) | ($30.28) |
| Diluted EPS | ($13.07) | ($17.93) | ($9.41) | ($18.79) | ($30.28) |
| Revenue Per Share | $5.07 | $13.36 | $17.88 | $19.18 | $28.78 |
| Shares | |||||
| Basic Shares Outstanding | 28.9M | 10.9M | 8.1M | 7.6M | 5.5M |
| Diluted Shares Outstanding | 28.9M | 10.9M | 8.1M | 7.6M | 5.5M |
| Profitability Metrics | |||||
| EBITDA | (175.9M) | (149.9M) | (38.6M) | (118.4M) | (139.3M) |
| D&A | 106.0K | 296.0K | 340.0K | 530.0K | 621.0K |
| EBIT | (176.0M) | (150.1M) | (38.9M) | (119.0M) | (139.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026